Cytoreductive surgery for advanced ovarian cancer: Cardiovascular evaluation with pulmonary artery catheters

1990 ◽  
Vol 37 (3) ◽  
pp. 311-314 ◽  
Author(s):  
Robin F. Eisner ◽  
Fredrick J. Montz ◽  
Jonathan S. Berek
Keyword(s):  
Ovarian Cancer ◽  
Pulmonary Artery ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Pulmonary Artery Catheters ◽  
Cardiovascular Evaluation

Maximal Cytoreductive Surgery and High Dose Cisplatin Chemotherapy for Advanced Ovarian Cancer

2010 ◽  
Vol 19 (4) ◽  
pp. 375-381 ◽  
Author(s):  
Kazunori Ochiai ◽  
Satoshi Takakura ◽  
Seiji Isonishi ◽  
Hiroshi Sasaki ◽  
Yoshiteru Terashima
Keyword(s):  
Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
High Dose

scholarly journals Bowel surgery by gynecologic oncologists during maximal cytoreductive surgery for advanced ovarian cancer

2021 ◽  
Author(s):  
Chi-Son Chang ◽  
Chel Hun Choi ◽  
Tae-Joong Kim ◽  
Jeong-Won Lee ◽  
Byoung-Gie Kim ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Bowel Surgery

Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients

2021 ◽  
Author(s):  
Mukur Dipi Ray ◽  
Suryanarayana S.V. Deo ◽  
Lalit Kumar ◽  
Manish Kumar Gaur
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Advanced Stages ◽  
Selection For ◽  
Selection Of Patients ◽  
Selection Of

In cases of ovarian carcinoma, primary cytoreductive surgery (CRS) is the standard treatment up to stage IIIB, but patient selection for neoadjuvant chemotherapy (NACT) in selected cases is controversial. A total of 200 patients with advanced ovarian cancer were analyzed retrospectively, according to specific selection criteria. Primary CRS was performed in 95 patients (47.5%) and interval CRS after 3–6 cycles of NACT was performed in 105 patients (52.5%). After median follow-up of 35 months, 5-year overall survival was 53.7% in the upfront CRS group and 42.2% in the NACT group. Primary CRS is the standard in advanced stages of ovarian carcinoma, but in certain subset of patients, NACT is preferred. Identifying that group is challenging but feasible. Proper selection of patients is key to successful outcomes.

Sign in / Sign up

Export Citation Format

Share Document